In the high-stakes world of biotech, where billions are poured into unproven science, Beacon Therapeutics emerges with a focused mission: restoring vision through gene therapy. Operating under the domain agtc.com, this isn't just another health tech startup—it's a calculated strike against genetic blindness with $185.1M in funding backing the vision.

"Gene therapy isn't just medicine—it's a permanent hardware upgrade for the human body. Beacon is writing the firmware for vision."

The tech stack tells its own story: WordPress for content, Tailwind and Bootstrap for UI, Cloudflare for security. It's pragmatic, not flashy. They're not wasting resources on custom builds when they need to focus on the science. The presence of PWA (Progressive Web App) capabilities hints at a forward-thinking approach to patient and physician engagement—critical in an industry where digital health integration is becoming non-negotiable.

• Leadership with deep pharma experience (Sue Washer, Janet Rae)
• Dual expertise in pharmacology AND regulatory affairs—a rare combo
• Focus on in vivo delivery systems (not just ex vivo approaches)
• Active social presence across LinkedIn, Twitter, Facebook